ArticleScientific reports2026
A deep learning-based multimodal model with automated body composition analysis predicts prognosis in advanced clear cell renal cell carcinoma.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Clear cell renal cell carcinoma (ccRCC) is an aggressive malignancy with a high risk of postoperative recurrence. Body composition has emerged as a prognostic marker, but its clinical use is hindered by manual measurement methods and poorly interpretable models. This study aimed to develop an automated, interpretable prediction model integrating deep learning-based body composition analysis to assess prognosis and explore underlying mechanisms in advanced ccRCC. This retrospective multicenter study included patients who underwent radical nephrectomy for advanced ccRCC. Body composition was quantified automatically from preoperative CT using a deep learning model (Comp2Comp). These metrics were integrated with clinicopathological features to build machine learning models for predicting 5-year survival and recurrence. Model performance was rigorously evaluated in an independent external cohort. To explore the biological basis of key imaging features, transcriptomic analysis and experimental validation were performed. Metrics for calibration and discrimination were used to compare the models. The multimodal model demonstrated robust predictive performance. The MLP model excelled in 5-year survival prediction (AUC 0.787 internal, 0.812 external), while the SVC model was optimal for recurrence (AUC 0.740 internal, 0.815 external). SHAP analysis identified visceral (VAT) and subcutaneous (SAT) adipose tissue as top predictive features. Subsequent transcriptomic analysis linked VAT to metabolic pathways and SAT to embryonic development programs. Protein expression of key associated genes was confirmed by immunohistochemistry. This study developed an automated multimodal prediction model by integrating deep learning-derived body composition metrics with clinicopathological features, demonstrating promising predictive performance in assessing survival and recurrence risks in advanced ccRCC, which was further supported by a preliminary external validation cohort. SHAP analysis identified visceral and subcutaneous adipose tissue as key predictors. Transcriptomic analysis linked VAT to pathways of mature renal function and SAT to embryonic developmental programs, providing initial insights into potential biological correlates of these imaging biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.